Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | XOMA |
---|---|---|
09:32 ET | 1377 | 25.9 |
11:31 ET | 100 | 25.655 |
11:45 ET | 100 | 25.7 |
12:14 ET | 250 | 25.675 |
01:10 ET | 250 | 25.7028 |
01:48 ET | 100 | 25.71 |
01:51 ET | 200 | 25.9 |
02:11 ET | 100 | 25.76 |
02:47 ET | 227 | 25.76 |
03:20 ET | 206 | 25.51 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
XOMA Corp | 296.8M | -6.5x | --- |
Actinium Pharmaceuticals Inc | 291.9M | -5.7x | --- |
Verastem Inc | 291.0M | -2.6x | --- |
Inovio Pharmaceuticals Inc | 310.9M | -2.2x | --- |
Atea Pharmaceuticals Inc | 307.4M | -2.2x | --- |
Invivyd Inc | 286.1M | -1.3x | --- |
XOMA Corporation is a biotechnology royalty aggregator. The Company’s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to larger pharmaceutical partners. The Company has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. Its royalty portfolio includes DAY101 (tovorafenib), JNJ-63723283 (cetrelimab), RZ358, arimoclomol, TAK-079 (mezagitamab), BAY-1213790 (osocimab), AFM13 (acimtamig), AB023 (gruticibart), AB002 (E-WE thrombin), AB054, AV-299 (ficlatuzumab), COM902, vosaroxin, aldoxorubicin, INCAGN2385, INCAGN02390, MNPR-101, PBF-680, PBF-677, PBF-999, PBF-1129, PBF-1650, G03-52-01, RZ402, DSUVIA (sufentanil sublingual tablet), IXINITY [coagulation factor IX (recombinant)], VABYSMO (faricimab-svoa), CMP-001 (vidutolimod), and CFZ533 (iscalimab).
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $296.8M |
---|---|
Revenue (TTM) | $5.8M |
Shares Outstanding | 11.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.84 |
EPS | $-3.92 |
Book Value | $7.72 |
P/E Ratio | -6.5x |
Price/Sales (TTM) | 51.1 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -665.67% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.